Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01828125 |
Recruitment Status :
Withdrawn
First Posted : April 10, 2013
Last Update Posted : December 4, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
In the unfortunate case of severe hypoglycaemia, glucagon is the first-line treatment because of its potent and rapid action starting as fast as 5 minutes after subcutaneous or intramuscular injection. Large dose of glucagon such as 1 mg subcutaneous is usually associated with undesirable side-effects such as nausea, vomiting, bloating and headache.
The overall objective of this research proposal is to assess the efficacy of lower subcutaneous doses of glucagon (0.1 mg or 0.2 mg) to correct hypoglycaemia compared to the standard dose (1.0 mg) in adults with type 1 diabetes mellitus (T1D).
It is postulated that much lower dosages of glucagon (0.1 or 0.2 mg) injected subcutaneously will be just as effective as the current recommended dose of 1.0 mg to correct hypoglycaemia without the undesirable gastro-intestinal side effects.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes | Procedure: Hypoglycaemic hyperinsulinemic clamp Drug: Glucagon | Phase 2 |
In the unfortunate case of severe hypoglycaemia, glucagon is the first-line treatment because of its potent and rapid action starting as fast as 5 minutes after subcutaneous or intramuscular injection. Current instructions for the treatment of severe hypoglycaemia call for the immediate injection of 1 mg of glucagon subcutaneously or intramuscularly. Large dose of glucagon such as 1 mg subcutaneous is usually associated with undesirable side-effects such as nausea, vomiting, bloating and headache. Moreover, glucagon emergency kits are relatively expensive (around $100 per kit), thus increasing the financial burden of diabetes on patients and the health care system.
The primary objective of this research project is to the study the pharmacological effects of different doses of glucagon injected subcutaneously to correct hypoglycaemia during controlled conditions mimicking a hypoglycaemic event in adults with type 1 diabetes. More specifically, we will be looking at the effects of subcutaneous glucagon injected at 0.1 or 0.2 mg and 1.0 mg to normalized plasma glucose during a hypoglycaemic hyperinsulinemic clamp in subjects with type 1 diabetes.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Treatment |
Official Title: | A Double-blinded, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Small Subcutaneous Glucagon Dose Against the Conventional 1 mg Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes |
Study Start Date : | April 2013 |
Estimated Primary Completion Date : | December 2013 |
Estimated Study Completion Date : | December 2013 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Hyperinsulinemic hypoglycaemic clamp 1mg glucagon
A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
|
Procedure: Hypoglycaemic hyperinsulinemic clamp
A first catheter will be inserted for infusion of D-[6,6-2H2] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-[6,6-2H2] glucose. A third catheter will be inserted for sampling. D-[6,6-2H2] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon. Drug: Glucagon |
Active Comparator: Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon
A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
|
Procedure: Hypoglycaemic hyperinsulinemic clamp
A first catheter will be inserted for infusion of D-[6,6-2H2] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-[6,6-2H2] glucose. A third catheter will be inserted for sampling. D-[6,6-2H2] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon. Drug: Glucagon |
- Incremental area under the curve of plasma glucose concentrations [ Time Frame: 30 minutes ]30-min incremental area under the curve of plasma glucose concentrations starting at the time glucagon is injected subcutaneously
- Time to reach glucose levels ≥ 4 mmol/L [ Time Frame: Up to 2.5 hours ]
- Time to reach glucose levels ≥ 5 mmol/L [ Time Frame: Up to 2.5 hours ]
- Time-to-peak plasma glucagon concentration [ Time Frame: Up to 2.5 hours ]Time-to-peak plasma glucagon concentration after glucagon injection
- Time for 25% of glucagon appearance [ Time Frame: Up to 2.5 hours ]Time for 25% of glucagon appearance after glucagon injection
- Time for 50% of glucagon appearance [ Time Frame: Up to 2.5 hours ]Time for 50% of glucagon appearance after glucagon injection
- Time for 75% of glucagon appearance [ Time Frame: Up to 2.5 hours ]Time for 75% of glucagon appearance after glucagon injection

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and females ≥ 18 years of old
- Clinical diagnosis of type 1 diabetes for at least two years.
Exclusion Criteria:
- Clinically significant nephropathy (MDRD < 60 mL/min/1.73 m2).
- Pregnancy
- Severe hypoglycemic episode within two weeks of screening
- Current use of glucocorticoid medication (except low stable dose)
- Pheochromocytoma or primary adrenal insufficiency (e.g. Addison's disease)
- Medical condition likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01828125
Canada, Quebec | |
Institut de recherches cliniques de Montréal | |
Montreal, Quebec, Canada, H2W 1R7 |
Principal Investigator: | Rémi Rabasa-Lhoret | Institut de recherches cliniques de Montréal |
Responsible Party: | Rémi Rabasa-Lhoret, Associate professor of Medicine, Institut de Recherches Cliniques de Montreal |
ClinicalTrials.gov Identifier: | NCT01828125 |
Other Study ID Numbers: |
Mini-doses glucagon |
First Posted: | April 10, 2013 Key Record Dates |
Last Update Posted: | December 4, 2013 |
Last Verified: | December 2013 |
Type 1 diabetes Hypoglycemia Glucagon Hypoglycaemic hyperinsulinemic clamp |
Diabetes Mellitus Diabetes Mellitus, Type 1 Hypoglycemia Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases |
Immune System Diseases Hypoglycemic Agents Glucagon Gastrointestinal Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |